内科学
内分泌学
胰高血糖素样肽-1
葡萄糖稳态
胰岛素
受体
胰岛素受体底物
胰高血糖素
2型糖尿病
胰高血糖素样肽1受体
胰岛素受体
胰岛素抵抗
化学
糖尿病
生物
医学
兴奋剂
作者
Patrice D. Cani,Claude Knauf,Miguel A. Iglesias,Daniel J. Drucker,Nathalie M. Delzenne,Rémy Burcelin
出处
期刊:Diabetes
[American Diabetes Association]
日期:2006-05-01
卷期号:55 (5): 1484-1490
被引量:400
摘要
Nondigestible fermentable dietary fibers such as oligofructose (OFS) exert an antidiabetic effect and increase the secretion of glucagon-like peptide 1 (GLP-1). To determine the importance of GLP-1 receptor-dependent mechanisms for the actions of OFS, we studied high-fat-fed diabetic mice treated with OFS for 4 weeks in the presence or absence of the GLP-1 receptor antagonist exendin 9-39 (Ex-9). OFS improved glucose tolerance, fasting blood glucose, glucose-stimulated insulin secretion, and insulin-sensitive hepatic glucose production and reduced body weight gain. Ex-9 totally prevented the beneficial effects of OFS. Furthermore, GLP-1 receptor knockout mice (GLP-1R−/−) were completely insensitive to the antidiabetic actions of OFS. At the molecular level, the effects of OFS on endogenous glucose production correlated with changes of hepatic IRS (insulin receptor substrate)-2 and Akt phosphorylation in an Ex-9-dependent manner. As inflammation is associated with diabetes and obesity, we quantified nuclear factor-κB and inhibitor of κB kinase β in the liver. The activity of both intracellular inflammatory effectors was reduced by OFS but, importantly, this effect could not be reverted by Ex-9. In summary, our data show that the antidiabetic actions of OFS require a functional GLP-1 receptor. These findings highlight the therapeutic potential of enhancing endogenous GLP-1 secretion for the treatment of type 2 diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI